Papers

Peer-reviewed International journal
2013

MicroRNA-196a is a putative diagnostic biomarker and therapeutic target for laryngeal cancer.

PloS one
  • Koichiro Saito
  • Koji Inagaki
  • Takahiro Kamimoto
  • Yoko Ito
  • Toshiaki Sugita
  • Satoko Nakajo
  • Akira Hirasawa
  • Arifumi Iwamaru
  • Takashi Ishikura
  • Hideki Hanaoka
  • Keisuke Okubo
  • Tokio Onozaki
  • Takeru Zama
  • Display all

Volume
8
Number
8
First page
e71480
Last page
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1371/journal.pone.0071480
Publisher
PUBLIC LIBRARY SCIENCE

BACKGROUND: MicroRNA (miRNA) is an emerging subclass of small non-coding RNAs that regulates gene expression and has a pivotal role for many physiological processes including cancer development. Recent reports revealed the role of miRNAs as ideal biomarkers and therapeutic targets due to their tissue- or disease-specific nature. Head and neck cancer (HNC) is a major cause of cancer-related mortality and morbidity, and laryngeal cancer has the highest incidence in it. However, the molecular mechanisms involved in laryngeal cancer development remain to be known and highly sensitive biomarkers and novel promising therapy is necessary. METHODOLOGY/PRINCIPAL FINDINGS: To explore laryngeal cancer-specific miRNAs, RNA from 5 laryngeal surgical specimens including cancer and non-cancer tissues were hybridized to microarray carrying 723 human miRNAs. The resultant differentially expressed miRNAs were further tested by using quantitative real time PCR (qRT-PCR) on 43 laryngeal tissue samples including cancers, noncancerous counterparts, benign diseases and precancerous dysplasias. Significant expressional differences between matched pairs were reproduced in miR-133b, miR-455-5p, and miR-196a, among which miR-196a being the most promising cancer biomarker as validated by qRT-PCR analyses on additional 84 tissue samples. Deep sequencing analysis revealed both quantitative and qualitative deviation of miR-196a isomiR expression in laryngeal cancer. In situ hybridization confirmed laryngeal cancer-specific expression of miR-196a in both cancer and cancer stroma cells. Finally, inhibition of miR-196a counteracted cancer cell proliferation in both laryngeal cancer-derived cells and mouse xenograft model. CONCLUSIONS/SIGNIFICANCE: Our study provided the possibilities that miR-196a might be very useful in diagnosing and treating laryngeal cancer.

Link information
DOI
https://doi.org/10.1371/journal.pone.0071480
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23967217
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743786
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000323221500087&DestApp=WOS_CPL
ID information
  • DOI : 10.1371/journal.pone.0071480
  • ISSN : 1932-6203
  • Pubmed ID : 23967217
  • Pubmed Central ID : PMC3743786
  • Web of Science ID : WOS:000323221500087

Export
BibTeX RIS